Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 9Thoracic 2Head & Neck 2Genitourinary 2Gastrointestinal 2Breast 2Sarcoma 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 8Carcinoma, Non-Small-Cell Lung 7Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Colorectal Neoplasms 5Breast Neoplasms 5Pancreatic Neoplasms 4Neoplasm Metastasis 4Urinary Bladder Neoplasms 3Stomach Neoplasms 3Sarcoma 3Prostatic Neoplasms 3Melanoma 3Kidney Neoplasms 3Head and Neck Neoplasms 3Uterine Cervical Neoplasms 2Urologic Neoplasms 2Triple Negative Breast Neoplasms 2Recurrence 2Ovarian Neoplasms 2Lung Neoplasms 2Endometrial Neoplasms 2Colonic Neoplasms 2Thyroid Neoplasms 1Soft Tissue Neoplasms 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pharyngeal Neoplasms 1Neurofibromatosis 2 1

Interventions

pembrolizumab 31Nivolumab 12Cyclophosphamide 10fludarabine 9aldesleukin 8atezolizumab 7durvalumab 6Magnetic Resonance Spectroscopy 6Trastuzumab 5Specimen Handling 5Paclitaxel 5Ipilimumab 5Docetaxel 5Biopsy 5fludarabine phosphate 4Radiotherapy 4Interleukin-2 4Gene Expression Profiling 4Carboplatin 4tisotumab vedotin 3cemiplimab 3aflibercept 3Polymerase Chain Reaction 3Immunoglobulin G 3Early Intervention, Educational 3Cisplatin 3Bevacizumab 3tremelimumab 2tislelizumab 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Cetuximab × Genitourinary × Clear all
NCT04485013 2026-02-18

TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers

Tizona Therapeutics, Inc

Phase 1 Recruiting
240 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡